June 2025 in “The Journal of Dermatology” Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
Baricitinib helps regrow hair in teens with severe alopecia areata.
April 2025 in “International Journal of Dermatology” Renaming frontal fibrosing alopecia to a syndrome could improve diagnosis and treatment.
February 2025 in “Actas Dermo-Sifiliográficas” Low-dose oral minoxidil can help improve hair and eyebrow growth in people with frontal fibrosing alopecia.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Alopecia areata severity and symptoms vary by race and ethnicity.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
October 2024 in “Dermatology Practical & Conceptual” Trichoscopy effectively diagnoses eyebrow hair loss in certain conditions.
October 2024 in “La Tunisie Médicale” Over half of alopecia areata patients in Tunisia experience depression, highlighting the need for psychological support.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
September 2024 in “Journal of the American Academy of Dermatology” Facebook groups play a crucial role in supporting and guiding patients on scalp cooling and hair loss during chemotherapy.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
August 2024 in “Journal of the American Academy of Dermatology” Baricitinib effectively promotes hair regrowth in both scalp and nonscalp areas for alopecia areata universalis patients.
July 2024 in “Medical alphabet” The SBN system effectively assesses alopecia areata severity and predicts its course.
July 2024 in “Journal of Investigative Dermatology” Alopecia areata causes negative emotions and stress due to hair loss and emotional triggers.
July 2024 in “Iranian journal of pathology” Frontal fibrosing alopecia mainly affects women over 50, causing hair loss and specific skin changes.
June 2024 in “Frontiers in immunology” Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.
Genetic testing can help diagnose skin conditions but needs more research for full effectiveness.
November 2023 in “Dermatology and Therapy” Baricitinib treatment helps regrow eyebrow, eyelash, and scalp hair in severe alopecia areata, improving patients' emotional well-being and quality of life.
November 2023 in “Indian Journal of Dermatology” The study found that Frontal Fibrosing Alopecia in North-East India mainly affects middle-aged women and is often associated with lichen planus pigmentosus.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Early treatment and multidisciplinary care are key to managing Frontal Fibrosing Alopecia and preventing further hair loss.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
September 2022 in “Journal of Investigative Dermatology” Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
September 2021 in “Revista interdisciplinar em saúde” Oral isotretinoin effectively stabilizes frontal fibrosing alopecia.
April 2019 in “Actas Dermo-Sifiliográficas” The conclusion is that having both Frontal Fibrosing Alopecia and Discoid Lupus Erythematosus may suggest a shared immune response in certain people, and a mix of antimalarial drugs and 5-alfa-reductase inhibitors is recommended for treatment.
March 2018 in “Dermatología Argentina” The study found that the average age of women diagnosed with Frontal Fibrosing Alopecia in Argentina is higher than in other countries, but their symptoms are similar.
January 2015 in “Journal of evolution of medical and dental sciences” Topical tacrolimus is effective and safe for treating alopecia areata.
November 2012 in “Annales de Dermatologie et de Vénéréologie” Frontal fibrosing alopecia can occur in children, not just postmenopausal women.